1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Valuation
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
ASPE
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
—
Shares Offered
—
—
Implied Upside vs Midpoint
Description
Aspen Neuroscience, Inc. is a leading, clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need. Our lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson’s disease (PD). We believe sasineprocel has the potential to be disease-modifying by primarily replacing a patient’s lost dopaminergic (DA) neurons with dopaminergic neuron precursor cells (DANPCs). In an ongoing Phase 1/2a ASPIRO clinical trial of sasineprocel in mid-stage to moderately advanced sporadic PD, patients have experienced, what we believe to be, sustained and clinically meaningful improvements in motor, quality of life, and non-motor symptoms as measured by comparison to clinically meaningful change benchmarks. Based on these findings, we believe sasineprocel has the potential to improve upon the current standard of care in PD and address the significant unmet need in PD for a disease-modifying therapy that may slow or halt the progression of this devastating disease. PD is a progressive neurodegenerative disease primarily characterized by the loss of DA neurons as well as impaired DA neurotransmission that results in the progressive deterioration of motor and non-motor neurological function. It is the second most common neurodegenerative disorder, estimated to affect more than one million people in the United States and more than 10 million people globally. The prevalence has doubled globally over the past 25 years, making it one of the fastest growing central nervous system (CNS) diseases. PD patients suffer from characteristic motor symptoms, including movement, coordination and speech impairments, as well as non-motor symptoms, including loss of sense of smell, sleep behavior disorders, difficulty swallowing, urinary symptoms, constipation, orthostatic hypotension, depression, psychosis, dementia and cognitive impairment. These symptoms can severely impact a patient’s quality of life, contribute to progressive disability and loss of independence, and are associated with increased morbidity and mortality over time. The current standard of care is palliative dopamine replacement therapy (DRT), including levodopa and dopamine agonists, which addresses motor symptoms but does not replace lost DA neurons, nor does it slow continued neuronal degeneration. DRT inadequately addresses non-motor symptoms, decreases in effectiveness over time, and is associated with side effects that can significantly impact patient quality of life. As DRT loses its effectiveness or as its side effects become intolerable, advanced therapies, such as deep brain stimulation (DBS), are considered. While DBS can be effective in addressing certain motor symptoms of PD, it has not been shown to slow disease progression in mid-stage to moderately advanced PD patients and can potentially worsen cognition, gait, speech and other axial symptoms. DBS has other drawbacks as well, including frequent long delays in access and optimization, and multiple invasive surgeries with permanent implanted hardware, which includes risks such as hemorrhage, infection, and device failure. In contrast to DRT and DBS, cell replacement therapy holds significant promise as an approach to restore and replace lost dopamine neurons and neural circuitry necessary for normal motor and non-motor function. We believe our cell replacement approach represents a promising therapy that could provide long-term benefits from a single administration without the need for permanently implanted hardware. Allogeneic approaches in development for PD can require one year or more of immunosuppressive therapy post-treatment, which is associated with increased risks of infection, organ toxicity, and metabolic complications. In contrast, autologous cell therapies are derived from a patient’s own cells, which reduces the risk of immune rejection after transplantation. Our clinical trial of sasineprocel has not required any immunosuppression post-administration and is designed to support the formation of functional synaptic connections and neural circuitry without the need for immune suppression. In a third-party preclinical study in non-human primate (NHP) models of PD, autologous DA progenitor cell transplantation survived without immunosuppression and integrated more robustly and produced more sustained motor improvements than allogeneic transplants. Moreover, our autologous iPSC approach is designed to require minimal cell expansion, which may reduce the opportunity for genomic abnormalities to arise and for cells harboring growth-promoting abnormalities to become selectively enriched during extended culture. While this is designed to be a one-time therapy, the autologous nature of the product could allow for redosing, if valuable over a patient’s multi-year course. We believe our autologous cell replacement strategy presents a significant advantage over both current standard-of-care therapies and allogeneic cell therapies in development for PD, and has the potential to deliver a tolerable, disease-modifying treatment with durable, long-term effectiveness. Sasineprocel and our end-to-end autologous iPSC platform are based on advances in cellular reprogramming, including the Nobel Prize–winning discovery by Shinya Yamanaka and John B. Gurdon, which demonstrated that mature, specialized cells can be reprogrammed into iPSCs through the introduction of defined transcription factors (commonly referred to as Yamanaka factors). We combine these foundational reprogramming methods with our stem cell biology expertise, the latest artificial intelligence, machine learning (ML) and genomic approaches to optimize cell identity, purity and functional potential and to enable a scalable, reproducible, standardized, and data-driven manufacturing process for autologous cell therapy. Sasineprocel, our proprietary autologous iPSC-derived composition of DANPCs, CNS progenitors, and glial progenitors, is designed to establish a biologically active cellular microenvironment that supports cell engraftment, survival, and functional integration of transplanted cells with the goal of restoring functional dopamine signaling in PD patients. We believe the sustained benefit that has been observed in certain patients treated with sasineprocel provides evidence of neural circuitry reconstruction and is further supported by preclinical studies, in which we observed that DANPCs transplanted into PD animal models differentiated into DA neurons that integrated into the brain and restored dopamine signaling. We hypothesize that sasineprocel’s combination of cells beyond DANPCs may play a key role in supporting neural synapse formation and general microenvironmental health to enable a broad and profound treatment effect in PD patients, including improvement in non-motor symptoms. --- We were incorporated in Delaware on May 18, 2018, under the name Aspen Biosciences, Inc. and changed our name to Aspen Neuroscience, Inc. in October 2018. Our principal executive offices are located at 10835 Road to the Cure, Suite 100, San Diego, CA 92121. Our telephone number is (858) 263-1222. Our website address is www.aspenneuroscience.com.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||